Real World, Open Label, QOL Assessment of Peanut Immunotherapy AR101 in Children and Adolescents

Key Inclusion Criteria: * Age 4 through 17 years * History of physician diagnosed IgE mediated peanut allergy with characteristic signs and symptoms * Positive SPT for peanut * Positive serum IgE to peanut * Written informed consent from the subject's parent/guardian * Written assent from the subject as appropriate * Use of effective birth control by sexually active female subjects of childbearing potential Key Exclusion Criteria: * Uncertain clinical diagnosis of peanut allergy * History of severe or life threatening episode of anaphylaxis or anaphylactic shock within 60 days of screening * Severe persistent asthma or uncontrolled mild or moderate asthma * History of eosinophilic esophagitis, other eosinophilic gastrointestinal disease, severe gastroesophageal reflux disease, symptoms of dysphagia or recurrent gastrointestinal symptoms of undiagnosed etiology * History of a mast cell disorder, including mastocytosis, urticarial pigmentosa, and hereditary or idiopathic angioedema * History of cardiovascular disease, including uncontrolled or inadequately controlled hypertension * History of chronic disease (other than asthma, atopic dermatitis, or allergic rhinitis) that is, or is at significant risk of becoming, unstable or requiring a change in chronic therapeutic regimen